ICCC · ImmuCell Corporation

ImmuCell Corporation delivered a strong start to 2026 with first quarter product sales surging 28.4% to $10.4 million, fueled by peak seasonal demand from the cow-calf segment and a 3% increase in U.S. scours biologicals market share. Gross margins expanded 340 basis points to 45.0%, reflecting higher production volumes, manufacturing efficiencies, and realized pricing improvements. This drove net income to $1.9 million, or $0.21 per basic share, up from $1.4 million last year. Management highlighted record revenue and output exceeding 450,000 units monthly, up from 380,000 in 2025, due to yield gains at the existing plant. Free cash flow of $3.4 million bolstered the cash position to $6.8 million, supporting net working capital of $14.9 million. A key strategic development was the $2 million net settlement from disputes with a former contract manufacturer, earmarked for First Defense capacity expansion amid plans for significant investment. Executives emphasized focus on commercial execution, customer contact, and yield improvements post-peak season, where revenue typically moderates. While no formal guidance was issued, confidence stems from market share gains despite prior backorder clearance impacts. The results underscore operational momentum in calf health biologics, with healthy inventory post-seasonal peaks and a strengthened balance sheet positioning the company for growth initiatives.